0

WHY THIS MATTERS IN BRIEF

By future standards today’s medicines and treatments are old fashioned, and we have an increasing array of powerful new tools at our disposal.

 

Love the Exponential Future? Join our XPotential Community, future proof yourself with courses from XPotential Universityconnect, watch a keynote, or browse my blog.

A little while ago scientists used gene editing tool CRISPR to create an E.Coli bacteria that was resistant to every known pathogen on Earth. Then, in 2018 a Chinese scientist used the same technology immorally on two unborn twins and made them resistant to a host of deadly diseases ranging from HIV to Meningitis. He was then arrested and jailed …

 

RELATED
Novoheart has grown real, miniature hearts in jars that beat like the real thing

 

These two experiments show just how powerful CRISPR is, or could be, when it comes to helping create designer humans resistant to disease – albeit an ethical, moral, and legal minefield.

Now though in a continuation of this work scientists have harnessed CRISPR gene-editing technology to block the replication of the novel coronavirus in human cells — an approach that could one day serve as a new treatment for COVID-19 and hopefully future pandemics.

However, unlike the other experiments, the study was performed in lab dishes and has not yet been tested on real animals or people, meaning a treatment based on the method could be years away.

 

RELATED
New electronics breakthrough lets devices run for years without batteries

 

CRISPR is a tool that enables researchers to precisely edit DNA. It’s based on a natural defense system used in bacteria that allows the microbes to target and destroy the genetic material of viruses, Live Science previously reported.

In the new study, published in the journal Nature Communications, the researchers used a CRISPR system that targets and destroys strands of RNA, rather than DNA. Specifically, their system uses an enzyme called Cas13b, which cleaves single strands of RNA, like those found in SARS-CoV-2, the virus that causes COVID-19.

The researchers designed CRISPR-Cas13b to target specific sites on the RNA of SARS-CoV-2; once the enzyme binds to the RNA, it destroys the part of the virus needed to replicate, according to a statement from the Peter MacCallum Cancer Centre in Victoria, Australia, which collaborated on the research.

 

RELATED
Simple paper blood test diagnoses disease faster and cheaper

 

“Once the virus is recognized, the CRISPR enzyme is activated and chops up the virus,” study lead author Dr. Sharon Lewin, of the Peter Doherty Institute for Infection and Immunity at the University of Melbourne, told AFP.

The researchers also found that their method worked even when new mutations were introduced into the SARS-CoV-2 genome, including those seen in the alpha coronavirus variant, first discovered in the UK.

Effective COVID-19 vaccines are currently being distributed around the world, but there remains a “clear and urgent need” for effective treatments for the disease, the authors said. They noted that there are “serious concerns” that the virus will evolve to “escape” current vaccines.

 

RELATED
Scientists create Nanobionic plants that detect chemicals and could grow on Mars

 

An ideal treatment would be an antiviral drug that patients take shortly after being diagnosed with COVID-19.

“This approach — test and treat —  would only be feasible if we have a cheap, oral and non-toxic antiviral. That’s what we hope to achieve one day with this gene scissors approach,” Lewin told AFP.

Although the new study is a first step toward such a treatment, it will likely be years before this method could be turned into a treatment that’s widely available, AFP reported. The researchers now plan to test the method in animal models, and eventually conduct clinical trials in people.

 

RELATED
Worlds first plug and play brain prosthesis tested successfully in the US

 

Medicines that use CRISPR technology have not yet been approved to treat any diseases, but multiple studies are underway to test CRISPR-based therapies in people as a treatment for various diseases, including cancer and HIV.

About author

Matthew Griffin

Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.

Your email address will not be published. Required fields are marked *